



GOVERNMENT OF PAKISTAN
(CABINET DIVISION)
INTELLECTUAL PROPERTY ORGANIZATION
THE PATENT OFFICE
KARACHI



To,

Dated: 27-10-2008

Mr. Munir Ahmed,
Director (Admn.),
IPO-Pakistan,
Islamabad.

Subject: WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE WEEKENDING 25-10-2008 TO BE PUBLISHED 05-11-2008 IN THE GAZETTE OF PAKISTAN PART-V.

Sir,

Reference to IPO letter dated 12-5-2008 forwarding therewith copy of letter No 18/IPO/2008/ RA-IV dated 23-4-2008 from Cabinet Division on the above subject.

A manuscript copies of the weekly notification regarding application filed, application accepted and sealing fee due is enclosed herewith for onward transmission to the Cabinet Division for Publication in the next issue of the Gazette of Pakistan (Part –V)

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 9215488

ENCL:

GOVERNMENT OF PAKISTAN
THE PATENT OFFICE
2nd Floor, Kandawala Building,
M.A. Jinnah Road,
Karachi

No.2/2/2003-F.Sec.

Dated: 27-10-2008

To,

Mr. Manzoor Ahmed
Section Officer
Cabinet Secretariat
Cabinet Division
Government of Pakistan
Islamabad

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 25-10-2008 TO BE PUBLISHED 05-11-2008 IN THE
GAZETTE OF PAKISTAN PART-V.**

Reference to Cabinet Secretariats letter No. 18/IPO/2008/RA-IV, dated 23rd April 2008. A manuscript copy of the weekly notification regarding application filed, application accepted and sealing fee due etc., is enclosed herewith for onward transmission to the Printing Corporation of Pakistan Press for publication in the next issue of the Gazette of Pakistan Part-V.

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 9215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

1239/2008	<u>20-10-2008</u> Schering Corporation, USA (Priority 22-10-07 USA)	“Bicyclic Heterocycle derivatives and methods of use thereof”
1240/2008	<u>21-10-2008</u> Janssen Pharmaceutica N.V. Belgium (Priority 31-10-07 USA)	“Stabilized pediatric suspension of carisbamate”
1241/2008	Janssen Pharmaceutica N.V. Belgium (Priority 25-10-07 USA)	“An arylindenopyrimidine and their use as an adenosine A2a receptor antagonists”
1242/2008	Janssen Pharmaceutica N.V. Belgium (Priority 24-10-07 USA)	“An arylindenopyrimidine compound and as an adenosine A2a receptor antagonists”
1243/2008	<u>22-10-2008</u> ACUCELA, INC., USA (Priority 01-11-07 USA)	“Amine derivative compounds for treating ophthalmic diseases and disorders”
1244/2008	Bayer CropScience AG, Germany (Priority 24-10-07 Europe)	“Herbicide combination”
1245/2008	Bayer CropScience AG, Germany (Priority 24-10-07 Europe)	“Herbicide combination”
1246/2008	Bayer CropScience AG, Germany (Priority 24-10-07 Europe)	“Herbicide combination”
1247/2008	Bayer CropScience AG, Germany (Priority 24-10-07 Europe)	“Herbicide combination”

1248/2008	Bayer CropScience AG, Germany (Priority 24-10-07 Europe)	“Herbicide combination”
1249/2008	Bayer CropScience AG, Germany (Priority 24-10-07 Europe)	“Herbicide combination”
1250/2008	Bayer CropScience AG, Germany (Priority 24-10-07 Europe)	“Salts of 2-iodo-N-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)carbamoyl benzene-sulfonamides, process for their preparation and their use as herbicides and plant growth regulators”
	<u>23-10-2008</u>	
1251/2008	ATLAS ELEKTRONIK GmbH Germany (Priority 07-11-07 Germany)	“Method for surveillance of a sea area”
1252/2008	ATLAS ELEKTRONIK GmbH Germany (Priority 12-11-07 Germany)	“Underwater antenna”
1253/2008	Huntsman Advanced Materials (Switzerland) GmbH Switzerland (Priority 25-10-07 Europe)	“Reactive dyes, processes for their preparation and their use”
1254/2008	AstraZeneca AB Sweden (Priority 25-10-07 Europe)	“Pyridine and pyrazine derivatives-083”
1255/2008	Sumitomo Chemical Company, Ltd. Japan (Priority 17-03-06 Japan) DIVISIONAL	“Pyridazine compound”
1256/2008	1. National Institute of Advanced Industrial Science and Technology 2. Otsuka Pharmaceutical Co., Ltd.	“Lipid-modified double-stranded RNA having potent RNA interference effect”

	Japan (Priority 24-10-07 Japan)	
1257/2008	Bayer Schering Pharma Oy Finland (Priority 22-11-07 Europe)	“Vaginal delivery system”
1258/2008	AstraZeneca AB Sweden (Priority 26-10-07 USA)	“Amino 1, 2, 4-triazole derivatives-as modulators of mglur5”
1259/2008	AstraZeneca AB Sweden (Priority 26-10-07 USA)	“Thiophene 1, 2, 4-triazole derivatives as modulators of mglur5”
1260/2008	AstraZeneca AB Sweden (Priority 26-10-07 USA)	“Fused pyrrolidine 1, 2, 4-triazole derivatives as modulators of mglur5”
1261/2008	MARICAP OY Pohjantahdentie Finland (Priority 24-10-07 Finland)	“Method and apparatus in a vacuum conveying of material”
1262/2008	Engr. Rehmat Wali Peshawar, Pakistan	“Tractor equipped with 20 to 30 HP diesel engine aeter origine power train and body structure”
	<u>24-10-2008</u>	
1263/2008	Amira Pharmaceuticals, Inc. USA (Priority 26-10-07 USA)	“5-lipoxygenase-activating protein (FLAP) inhibitor”
1264/2008	1.Novartis AG, 2.University of Zurich Switzerland (Priority 02-11-07 Europe)	“Improved NOGO-A binding molecules and pharmaceutical use thereof”
1265/2008	Honda Motor Co., Ltd. Japan (Priority 29-1-08 Japan)	“Decompression unit engine”
1266/2008	Honda Motor Co., Ltd. Japan (Priority 30-10-07 Japan)	“Receiving system for vehicle”

1267/2008	P2i Ltd. United Kingdom (Priority 30-10-07 UK)	“Novel method”
1268/2008	Unilever Plc., United Kingdom (Priority 05-11-07 Europe)	“Process for manufacturing tea products”
1269/2008	Unilever Plc., United Kingdom (Priority 21-11-07 India)	“Novel detergent bars”
1270/2008	Unilever Plc., United Kingdom (Priority 05-11-07 Europe)	“Process for the manufacturing tea products”
1271/2008	<u>25-10-2008</u> VIALACTIA BIOSCIENCES (NZ) LIMITED, New Zealand (Priority 26-10-07 USA)	“Polynucleotides and methods for the improvement of plants”
1272/2008	Otsuka Pharmaceutical Co., Ltd. Japan (Priority 30-10-07 Japan)	“Heterocyclic compound and pharmaceutical composition thereof”

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.


Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

106/1997 Glaxo Group Limited, “Substituted -4-hydroxy-phenylalcanoic acid
Great Britain compound”

(CO7D, 333/32, A61K, 31/19)


139831

A compound having the formula (I):



Wherein

A is selected from the group consisting of:

- (i) phenyl, wherein said phenyl is optionally substituted by one or more halogen atoms, C₁₋₆alkyl, C₁₋₃alkoxy, C₁₋₃ fluoroalkoxy, or NR⁷R⁸ where R⁷ and R⁸ are independently hydrogen or C₁₋₃alkyl;
- (ii) a 5- or 6- membered heterocyclic group containing at least one heteroatom selected from oxygen, nitrogen and sulfur: and
- (iii) a fused bicyclic ring 

wherein ring C represents a heterocyclic group as defined in point (ii) above, which bicyclic ring is attached to group B via ring atom of ring C;

B is selected from the group consisting of;

- (iv) C₁₋₆ alkylene;
- (v) -MC₁₋₆alkylene or C₁₋₆alkyleneMC₁₋₆alkylene, wherein M is O, S, or -NR² wherein R² represents hydrogen or C₁₋₃alkyl;
- (vi) a 5- or 6- membered heterocyclic group containing at least one nitrogen heteroatom and optionally at least one further heteroatom selected from oxygen, nitrogen and sulfur and optionally substituted by C₁₋₃alkyl; and
- (vii) Het-C₁₋₆ alkylene, wherein Het represents a heterocyclic group as defined in point (vi) above;

Alk represents C₁₋₃ alkylene;


R₁ represents hydrogen or C₁₋₃ alkyl;

Z is selected from the group consisting of:

- (viii) -(C₁₋₃ alkylene) phenyl, which phenyl is optionally substituted by one or more halogen atoms; and
- (ix) -NR³R⁴, wherein R³ represents hydrogen or C₁₋₃ alkyl, and R⁴ represents -Y-(C=O)-T-R⁵, or -Y-(CH(OH)-T-R⁵), wherein:
 - (a) Y represents a bond, C₁₋₆ alkylene, C₂₋₆ alkenylene, C₄₋₆ cycloalkylene or cycloalkenylene, a heterocyclic group as defined in point (vi) above, or phenyl optional substituted by one more C₁₋₃ alkyl groups and/or one or more halogen atoms;
 - (b) T represents a bond, C₁₋₃ alkyleneoxy, -O- or -N(R⁶)-, wherein R⁶ represents hydrogen or C₁₋₃ alkyl;

(c) R⁵ represents C₁₋₆ alkyl, C₄₋₆ cycloalkyl or cycloalkenyl, phenyl (optionally substituted by one or more: halogen atoms, C₁₋₃ alkyl, C₁₋₃ alkoxy groups, C₀₋₃ alkylene NR⁹R¹⁰ where each R⁹ and R¹⁰ is independently hydrogen, C₁₋₃ alkyl, -SO₂ C₁₋₃ alkyl, or -CO₂ C₁₋₃ alkyl SO₂NHC₁₋₃ alkyl, CO-3 alkylene CO₂H, C₀₋₃ alkylene CO₂C₁₋₃ alkyl, or -OCH₂C(O)NH₂), a 5- or 6-membered heterocyclic group as defined in point (ii) above,

(d) Or a bicyclic fused ring



wherein ring D represents a 5- or 6-membered heterocyclic group containing at least one heteroatom selected from oxygen, nitrogen and sulfur and optionally substituted by (=A), which bicyclic ring is attached to T via a ring atom of ring D, or -C₁₋₆ alkyleneMR₁₁ M is O, S, or -NR₂ wherein R₂ and R₁₁ are independently hydrogen or C₁₋₃ alkyl.

520/2001	Celltech Chiroscience Limited. United Kingdom	“Antibody having specificity for TNFα (C12N, 15/13, A61P, 19/02, A61P, 37/06)
----------	--	--

139832

There is disclosed antibody molecules containing at least at least one CDR derived from a mouse monoclonal antibody having specificity for human TNFα. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNFα,

939/2004	HF Arzneimittelforschung GmbH. Germany	“A method for producing a pharmaceutical composition comprising deoxypeganine” (A61K, 31/517)
----------	--	--

139833

248/2005 Akzo Nobel N.V.
The Netherlands

The present invention pertains to a method for producing a pharmaceutical composition for treating a schizophrenic psychosis, and to pharmaceutical composition for treating a schizophrenic psychosis, wherein said pharmaceutical composition comprises deoxypeganine.

“X-Ray visible drug delivery device”

(A61K, 49/04, A61K, 51/00)

139834

The subject invention provides an X-ray visible drug delivery device for subdermal administration of a contraceptive or hormone replacement therapy comprising one compartment consisting of (i) a thermoplastic polymer core loaded with (a) a contraceptively effective or therapeutically effective amount of desogestrel or 3- ketodesogestrel and (b) about 4-30% by weight radio-opaque material and (ii) a non-medicated thermoplastic polymer skin covering the core. The subject invention further provides an X-ray visible drug delivery device for subdermal administration of a contraceptive or hormone replacement therapy comprising one compartment consisting of (i) a thermoplastic polymer core loaded with a contraceptively effective or therapeutically effective amount of desogestrel or 3-ketodesogestrel and containing an inert metal wire and (ii) a non-mediated thermoplastic polymer skin covering the core.


1119/2005 Aventis Pharma S.A.
France

“Substituted 2-alkoxy-3,4,5-trihydroxy-alkylamide compound”

(CO7D, 223/12, A61K, 31/55)

139835

2-alkoxy-3,4,5-trihydroxy-alkylamide, preparation thereof, composition containing it and use thereof. The present invention relates especially to 2-alkoxy-3,4,5-trihydroxy-alkylamide, to its preparation, to composition containing it and to its use as medicaments, in particular as anticancer agents.




169-A/2006 Eli Lilly and Company, USA.

“Substituted imidazo[1,2-a] pyridinyl compound”

(CO7D, 471/04)

139836

The present invention provide compound that is inhibitor of VEGF-R2 of the formula:



(I)

and method of using this compound.

709/2007 DyStar Testilfarben GmbH, Germany

“Dye mixture of fiber-reactive azo dyes”


(C09B, 62/44, C09B, 62/475)

139837


Dye mixture of fiber-reactive azo dyes, their preparation and their use

The present invention concerns a dye mixture comprising at least one dye of the general formula (I)


(I)



and at least one dye of the general formula (II)



and/or at least one dye of the general formula (III)



Where the variables are as defined in claim 1, dyes of the general formula (I), processes for their preparation and their use.

730/2007

Picanol N.V.,
Belgium

“Lifting heddle for a wear resistive device for forming a leno weave”

(D03C, 7/02)

139838

A device (100) and a lifting heddle for a device (100) for moving leno warp threads (501, 502) to form a leno weave (505), the device (100) comprising lifting heddles (200,300) and a doup heddle (400), whereby the lifting heddle (200, 300) comprising an upper part (210,310) and a lower part (220, 320) and whereby at least at the section (221,321) of the lifting heddle (200,300) a wire (230,240,330,340) is arranged on the lifting heddle (200,300) for guiding a leno warp thread (501,502) along the lifting heddle (200,300).

786/2008


Eli Lilly and
Company,
USA.

“Pharmaceutically acceptable salt of a substituted imidazo [1,2-a] pyridinyl compound”

(CO7D, 471/04)

139839

The present invention provide pharmaceutically acceptable salt of compound that is inhibitor of VEGF-R2 of the formula:



(I)

and method of using this compound.

④④④④④④④④

SEALING FEES DUE

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

139485	Pfizer Ireland Pharmaceuticals., Ireland	866/1999
139486	Novartis ATG., Switzerland	318/2000
139487	Smithkline Beecham P.l.c., United Kingdom	1048/2000
139488	AstraZeneca AB Sweden	793/2001
139489	Bristol-Myers Squibb Company., USA	704/2003
139490	1. ENI S.P.A. 2. Polimeri Europa S.P.A. Italy	932/2006
139491	Smithkline Beecham P.l.c. United Kingdom	1096/2006
139492	Bristol-Myers Squibb Company., USA	1112/2006
139493	Arthur Benjamin O' Connor., Australia	1294/2006
139494	Clariant Internatgional Limited., Switzerland	1336/2006
139495	Clariant International Limited., Switzerland	1337/2006
139496	Methanol Casale S.A., Switzerland	1472/2006
139497	Bayer HealthCare LLC., USA	1561/2006

(MRS. YASMEEN ABBASI)
CONTROLLER OF PATENTS
Tel: 9215488